IBRX Stock Price Live, Key Points and Company Profile
7 mins read

IBRX Stock Price Live, Key Points and Company Profile

IBRX Stock Price


IBRX Stock Price Live – Here

IBRX Stock Price Live

IBRX Company Profile

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company’s platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme.


Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.

IBRX Stock Price FAQs

What’s the current market cap for ImmunityBio stock?

ImmunityBio (IBRX) has a market cap of $5.3B as of May 20, 2024.

What is the P/E ratio for ImmunityBio stock?

The price to earnings (P/E) ratio for ImmunityBio (IBRX) stock is 0 as of May 20, 2024.

Does ImmunityBio stock pay dividends?

No, ImmunityBio (IBRX) stock does not pay dividends to its shareholders as of May 20, 2024.


When is the next ImmunityBio dividend payment date?

ImmunityBio (IBRX) stock does not pay dividends to its shareholders.

What is the beta indicator for ImmunityBio?

ImmunityBio (IBRX) has a beta rating of 0.93. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the ImmunityBio stock price target?

The target price for ImmunityBio (IBRX) stock is $7.5, which is 1.96% below the current price of $7.65. This is an average based on projections from 2 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice – Lightyear does not carry out investment research.

What was ImmunityBio’s price range in the past 12 months?

ImmunityBio lowest stock price was $1.25 and its highest was $10.53 in the past 12 months.


What is ImmunityBio’s market cap?

ImmunityBio’s market cap is $5.29B.

When is ImmunityBio’s upcoming earnings report date?

ImmunityBio’s upcoming earnings report date is Aug 09, 2023 which is 285 days ago.

How were ImmunityBio’s earnings last quarter?

ImmunityBio released its earnings results on May 11, 2023. The company reported -$0.27 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.27.

Is ImmunityBio overvalued?

According to Wall Street analysts ImmunityBio’s price is currently Overvalued.

Does ImmunityBio pay dividends?

ImmunityBio does not currently pay dividends.


What is ImmunityBio’s EPS estimate?

ImmunityBio’s EPS estimate is -$0.24.

How many shares outstanding does ImmunityBio have?

ImmunityBio has 691,567,930 shares outstanding.

What happened to ImmunityBio’s price movement after its last earnings report?

ImmunityBio reported an EPS of -$0.27 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -10.215%.

Which hedge fund is a major shareholder of ImmunityBio?

Among the largest hedge funds holding ImmunityBio’s share is Perceptive Advisors LLC. It holds ImmunityBio’s shares valued at 6M.

What is the current share price of Immunitybio Inc (IBRX)?

The share price of Immunitybio Inc (IBRX) is $7.65 (NASDAQ) as of 17-May-2024 16:12 EDT. Immunitybio Inc (IBRX) has given a return of -20.33% in the last 3 years.


What is the market cap of Immunitybio Inc (IBRX)?

Immunitybio Inc (IBRX) has a market capitalisation of $ 5,291 Mln as on 17-May-2024. As per Value Research classification, it is a Small Cap company.

How can you buy shares of Immunitybio Inc (IBRX)?

Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Immunitybio Inc (IBRX) and enter the required number of quantities and click on buy to purchase the shares of Immunitybio Inc (IBRX).

What is the main business of Immunitybio Inc (IBRX)?

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company’s platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme.


Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.

Who are the promoters/managers of Immunitybio Inc (IBRX)?

The CEO & director of Dr. Patrick Soon-Shiong F.A.C.S., FRCS (C), M.Sc.. is Immunitybio Inc (IBRX), and CFO & Sr. VP is Mr. Richard Gerald Adcock.

What is the total promoter pledging in Immunitybio Inc (IBRX)?

There is no promoter pledging in Immunitybio Inc (IBRX).


Read our More Articles

  1. Sunrun Stock Price Chart, Overview, Stats, Company Profile
  2. NVTA Stock Forecast 2025/Invitae Corp Stock Price Forecast for 2025


One thought on “IBRX Stock Price Live, Key Points and Company Profile

Leave a Reply

Your email address will not be published. Required fields are marked *